Физиологическая роль и клинические эффекты мелатонина


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Мелатонин обладает широким спектром активности, но основная его функция - нормализация сна. Приводятся данные клинических исследований, позволяющие расширить показания к применению препаратов мелатонина.

Полный текст

Доступ закрыт

Об авторах

С. Леваков

Первый МГМУ им. И.М. Сеченова

Е. Боровкова

Первый МГМУ им. И.М. Сеченова

Email: katyanikitina@mail.ru

Список литературы

  1. Ariens-Kappers J. Innervation of the Epiphysis cerebri in the albino rat // Anat. Rec. - 1960; 136: 220.
  2. Axelrod J., Shein H., Wurtman R. Stimulation of C14-melatonin synthesis from C14-tryptophan by noradrenaline in rat pineal in organ culture // Proc. Natl. Acad. Sci. USA. - 1969; 62: 544.
  3. Anisimov V., Alimova I., Baturin D. et al. Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice // Exp. Gerontol. - 2003; 38: 449.
  4. Aoki H., Yamada N., Ozeki Y. et al. Minimum light intensity required to suppress nocturnal melatonin concentration in human saliva // Neurosci. Lett. -1998; 252: 91.
  5. Atkinson G., Jones H., Edwards B. et al. Effects of daytime ingestion of melatonin on short-term athletic performance // Ergonomics. - 2005; 48: 1512.
  6. Bonn, D. Melatonin's multifarious marvels: Miracle or myth? // Lancet. -1996; 347: 184.
  7. Brzezinski A. Melatonin in humans // N. Engl. J. Med. - 1997; 336: 186.
  8. Brzezinski A., Vangel M., Wurtman R. et al. Effects of exogenous melatonin on sleep: a meta-analysis // Sleep Med. Rev. - 2005; 9: 41.
  9. Buscemi N., Vandermeer B., Pandya R. et al. Melatonin for treatment of sleep disorders. Summary, evidence report/technology assessment: Number 108. AHRQ Publication Number 05-E002-1, November 2004. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/epcsums/melatsum.htm (Accessed on September 23, 2011).
  10. Buscemi N., Vandermeer B., Hooton N. et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis // J. Gen. Intern. Med. - 2005; 20: 1151.
  11. Cagnacci A., Cannoletta M., Renzi A. et al. Prolonged melatonin administration decreases nocturnal blood pressure in women // Am. J. Hypertens. - 2005; 18: 1614.
  12. Duell P., Wheaton D., Shultz A. et al. Inhibition of LDL oxidation by melatonin requires supraphysiologic concentrations // Clin. Chem. - 1998; 44: 1931-36.
  13. Ekman A., Leppäluoto J., Huttunen P. et al. Ethanol inhibits melatonin secretion in healthy volunteers in a dose-dependent randomized double blind cross-over study // J. Clin. Endocrinol. Metab. - 1993; 77: 780.
  14. Erman M., Seiden D., Zammit G. et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia // Sleep Med. - 2006; 7: 17.
  15. Fiske V., Bryant K., Putnam J. Effect of light on the weight of pineal in the rat // J. Endocrinol. - 1960; 66: 489.
  16. Grossman E., Laudon M., Yalcin R. et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension // Am. J. Med. - 2006; 119: 898.
  17. Gerdin M., Masana M., Rivera-Bermúdez M. et al. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin // FASEB J. - 2004; 18: 1646.
  18. Gerdin M., Masana M., Dubocovich M.L. Melatonin-mediated regulation of human MT(1) melatonin receptors expressed in mammalian cells // Biochem. Pharmacol. - 2004; 67: 2023-30.
  19. Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders // Curr. Opin. Investig. Drugs. -2009; 10: 691.
  20. Jonas M., Garfinkel D., Zisapel N. et al. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients // Blood Press. - 2003; 12: 19.
  21. Kitay J., Altschule M. Effects of pineal extract administration on ovary weight in rats // Endocrinol. - 1954; 55: 782.
  22. Klein D. The pineal gland: A model of neuroendocrine regulation. In: The Hypothalamus, Reichlin S., Baldessarini R., Martin J. (Eds) / New York: Raven Press, 1978; p. 303.
  23. Kopin I., Pare C., Axelrod J., et al. 6-Hydroxylation, the major metabolic pathway for melatonin // Biochim. Biophys. Acta. - 1960; 40: 377.
  24. Kennaway D., Stamp G., Goble F. Development of melatonin production in infants and the impact of prematurity // J. Clin. Endocrinol. Metab. - 1992; 75: 367.
  25. Lewy A., Wehr T., Goodwin F. et al. Lights up presses melatonin secretion in humans // Science. - 1980; 210: 1267.
  26. Lerner A., Case J., Takahashi Y. et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes // J. Am. Chem. Soc. - 1958; 80: 2587.
  27. Lynch H. Diurnal oscillations in pineal melatonin content // Life Sci. - 1971; 10: 791.
  28. Lynch H., Wurtman R., Moskowitz M. et al. Daily rhythm in human urinary melatonin // Science. - 1975; 187: 169.
  29. Lynch H., Jimerson D., Ozaki Y. et al. Entrainment of rhythmic melatonin secretion in man to a 12-hour phase shift in the light/dark cycle // Life Sci. - 1978; 23: 1557.
  30. Moore R., Klein D. Visual pathways and the central neural control of a circadian rhythm in pineal serotonin N-acetyltransferase activity // Brain Res. -1974; 71: 17.
  31. Pappolla M., Bozner P., Soto C. et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin // J. Biol. Chem. - 1998; 273: 7185.
  32. Pappolla M., Chyan Y., Poeggeler B. et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease // J. Neural. Transm. - 2000; 107: 203.
  33. Rodriguez C., Mayo J., Sainz R. et al. Regulation of antioxidant enzymes: a significant role for melatonin // J. Pineal. Res. - 2004; 36: 1.
  34. Röjdmark S., Wikner J., Adner N. et al. Inhibition of melatonin secretion by ethanol in man // Metabolism. - 1993; 42: 1047.
  35. Tricoire H., Locatelli A., Chemineau P. et al. Melatonin enters the cerebrospinal fluid through the pineal recess // Endocrinology. - 2002; 143: 84.
  36. Waldhauser F., Lynch H., Wurtman R. Melatonin in human body fluids: Clinical significance. In: The Pineal Gland (Comprehensive Endocrinology), Reiter R. (Ed) / New York: Raven Press, 1984; p. 345.
  37. Waldhauser F., Lieberman H., Lynch H. et al. A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol // Neuroendocrinology. - 1987; 46: 125.
  38. Wang L., Suthana N., Chaudhury D. et al. Melatonin inhibits hippocampal long-term potentiation // Eur. J. Neurosci. - 2005; 22: 2231.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах